Current and Emerging Therapies for COVID-19 in Lung Transplantation.

Autor: Friedman DZP; 5841 South Maryland Avenue, MC 5065, Chicago, IL 60637 USA Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine., Pettit NN; Chicago, IL USA Department of Pharmacy, University of Chicago Medicine., MacKenzie E; Kansas City, KS USA Department of Medicine, Section of Infectious Diseases, University of Kansas Health System., Pisano J; 5841 South Maryland Avenue, MC 5065, Chicago, IL 60637 USA Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine.
Jazyk: angličtina
Zdroj: Current pulmonology reports [Curr Pulmonol Rep] 2023; Vol. 12 (2), pp. 23-35. Date of Electronic Publication: 2023 Feb 16.
DOI: 10.1007/s13665-023-00302-3
Abstrakt: Purpose of Review: The landscape of the coronavirus disease 2019 (COVID-19) pandemic has rapidly changed over the past 3 years. Paralleling this evolution, the scientific and medical communities have reported many novel findings relating to the infection's epidemiology, transmission, diagnosis, and treatment. We review pertinent studies of COVID-19 therapeutics with an emphasis on their application to lung transplant recipients.
Recent Findings: Agents that have been well-studied for treating COVID-19 include antivirals (remdesivir, nirmatrelvir/ritonavir, molnupiravir), monoclonal antibodies, and immunomodulators (for example, corticosteroids and tocilizumab).
Summary: Remdesivir remains an essential therapy for managing mild-moderate COVID-19. Though highly efficacious for mild-moderate COVID-19 for outpatient therapy, ritonavir-boosted nirmatrelvir has limited use in lung transplant recipients due to significant drug-drug interactions. Monoclonal antibodies, though useful, are the most affected by the emergence of new viral variants.
Competing Interests: Conflict of InterestDZP Friedman declares that he has no conflicts of interest. N Pettit declares that she has no conflicts of interest. E Mackenzie declares that she has no conflicts of interest. J Pisano receives grant support from Pfizer, Moderna, and Gilead.
(© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
Databáze: MEDLINE
Externí odkaz: